About Idorsia Ltd

Company Description

Idorsia is a high-potential biopharmaceutical company, with an experienced team of over 1,200 highly qualified professionals, a full R&D pipeline, state-of-the-art facilities, and a strong balance sheet – the ideal constellation for bringing successful medicines to the market.

We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.

Idorsia is specialized in the discovery and development of small molecules, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified and balanced development pipeline, covering multiple therapeutic areas.

Year founded

2017

Served area

Worldwide

Headcount

1,200

Headquarters

Hegenheimermattweg 91, 4123 Allschwil – Switzerland

Shareholder information

Shares outstanding

176,966,995

IPO

June 16, 2017

Stock exchange(s)

SIX Swiss Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.